Core binding factor beta plays a critical role by facilitating the assembly of the Vif-Cullin 5 E3 ubiquitin ligase

Journal of Virology

Volumn 88, Issue 6, 2014, Pages 3309-3319

  Fribourgh, Jennifer L ^a   Nguyen, Henry C ^a   Wolfe, Leslie S ^a,e   DeWitt, David C ^a   Zhang, Wenyan ^c   Yu, Xiao Fang ^d   Rhoades, Elizabeth ^a,b   Xiong, Yong ^a  

^a YALE UNIVERSITY   (United States)

^b Yale University   (United States)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e KBI Biopharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CORE BINDING FACTOR BETA; CULLIN; CULLIN 5; ELONGIN B; ELONGIN C; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VIF PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GEL PERMEATION CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; RESIDUE ANALYSIS; VIRUS INFECTIVITY;

CELL LINE; CORE BINDING FACTOR BETA SUBUNIT; CULLIN PROTEINS; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN BINDING; TRANSCRIPTION FACTORS; UBIQUITIN-PROTEIN LIGASES; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84894528274     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03824-13     Document Type: Article

References (41)

1. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-809. http://dx.doi.org/10.1016/S0092-8674(03)00423-9.
2. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112. http://dx.doi.org/10.1126/science.1083338.
3. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by humanAPOBEC3Gthrough lethal editing of nascent reverse transcripts. Nature 424:99-103. http://dx.doi.org/10.1038/nature01709.
4. Mariani R, Chen D, Schröfelbauer B, Navarro F, König R, Bollman B, Münk C, Nymark-McMahon H, Landau NR. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114:21-31. http://dx.doi.org/10.1016/S0092-8674(03)00515-4.
5. Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:1398-1403. http://dx.doi.org/10.1038/nm946.
6. Zhang H, Yang B, Pomerantz RJ, Zhang CM, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98. http://dx.doi.org/10.1038/nature01707.
7. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15:166-170. http://dx.doi.org/10.1016/j.cub.2004.12.068.
8. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80: 8450-8458. http://dx.doi.org/10.1128/JVI.00839-06.
9. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 282:2587-2595. http://dx.doi.org/10.1074/jbc.M607298200.
10. Conticello SG, Harris RS, Neuberger MS. 2003. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr. Biol. 13:2009-2013. http://dx.doi.org/10.1016/j.cub.2003.10.034.
11. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-1407. http://dx.doi.org/10.1038/nm945.
12. Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601. http://dx.doi.org/10.1016/S1097-2765(03)00353-8.
13. Yu XH, Yu YK, Liu BD, Luo K, Kong W, Mao PY, Yu XF. 2003. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-1060. http://dx.doi.org/10.1126/science.1089591.
14. Mehle A, Goncalves J, Santa-Marta M, McPike M, Gabuzda D. 2004. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes Dev. 18:2861-2866. http://dx.doi.org/10.1101/gad.1249904.
15. Yu Y, Xiao Z, Ehrlich ES, Yu X, Yu XF. 2004. Selective assembly of HIV-1 Vif-Cul5-elonginB-elonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes Dev. 18:2867-2872. http://dx.doi.org/10.1101/gad.1250204.
16. Stanley BJ, Ehrlich ES, Short L, Yu Y, Xiao Z, Yu XF, Xiong Y. 2008. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J. Virol. 82:8656-8663. http://dx.doi.org/10.1128/JVI.00767-08.
17. Luo K, Xiao Z, Ehrlich E, Yu Y, Liu B, Zheng S, Yu XF. 2005. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proc. Natl. Acad. Sci. U.S.A. 102:11444-11449. http://dx.doi.org/10.1073/pnas.0502440102.
18. Mehle A, Thomas ER, Rajendran KS, Gabuzda D. 2006. A zinc-binding region in Vif binds cul5 and determines cullin selection. J. Biol. Chem. 281:17259-17265. http://dx.doi.org/10.1074/jbc.M602413200.
19. Paul I, Cui J, Maynard EL. 2006. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 103: 18475-18480. http://dx.doi.org/10.1073/pnas.0604150103.
20. Xiao Z, Ehrlich E, Yu Y, Luo K, Wang T, Tian C, Yu XF. 2006. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 349:290-299. http://dx.doi.org/10.1016/j.virol.2006.02.002.
21. Xiao Z, Ehrlich E, Luo K, Xiong Y, Yu XF. 2007. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB J. 21:217-222. http://dx.doi.org/10.1096/fj.06-6773com.
22. Dang Y, Davis RW, York IA, Zheng YH. 2010. Identification of 81LGXGXXIXW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84:5741-5750. http://dx.doi.org/10.1128/JVI.00079-10.
23. Dang Y, Wang X, Zhou T, York IA, Zheng YH. 2009. Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. J. Virol. 83:8544-8552. http://dx.doi.org/10.1128/JVI.00651-09.
24. Dang Y, Wang X, York IA, Zheng YH. 2010. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity. J. Virol. 84: 8561-8570. http://dx.doi.org/10.1128/JVI.00960-10.
25. Tian CJ, Yu XH, Zhang W, Wang T, Xu RZ, Yu XF. 2006. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80:3112-3115. http://dx.doi.org/10.1128/JVI.80.6.3112-3115.2006.
26. Pery E, Rajendran KS, Brazier AJ, Gabuzda D. 2009. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83:2374-2381. http://dx.doi.org/10.1128/JVI.01898-08.
27. Russell RA, Pathak VK. 2007. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81:8201-8210. http://dx.doi.org/10.1128/JVI.00395-07.
28. Jager S, Kim DY, Hultquist JF, Shindo K, LaRue RS, Kwon E, Li M, Anderson BD, Yen L, Stanley D, Mahon C, Kane J, Franks-Skiba K, Cimermancic P, Burlingame A, Sali A, Craik CS, Harris RS, Gross JD, Krogan NJ. 2012. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-375. http://dx.doi.org/10.1038/nature10693.
29. Zhang W, Du J, Evans SL, Yu Y, Yu XF. 2012. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-379. http://dx.doi.org/10.1038/nature10718.
30. de Bruijn MF, Speck NA. 2004. Core-binding factors in hematopoiesis and immune function. Oncogene 23:4238-4248. http://dx.doi.org/10.1038/sj.onc.1207763.
31. Ito Y. 2008. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv. Cancer Res. 99:33-76. http://dx.doi.org/10.1016/S0065-230X(07)99002-8.
32. Hultquist JF, Binka M, LaRue RS, Simon V, Harris RS. 2012. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. J. Virol. 86:2874-2877. http://dx.doi.org/10.1128/JVI.06950-11.
33. Salter JD, Lippa GM, Belashov IA, Wedekind JE. 2012. Core-binding factor beta increases the affinity between human cullin 5 and HIV-1 Vif within an E3 ligase complex. Biochemistry 51:8702-8704. http://dx.doi.org/10.1021/bi301244z.
34. Zhou XH, Evans SL, Han X, Liu YY, Yu XF. 2012. Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBF beta and CRL5 E3 ubiquitin ligase components. PLoS One 7:e33495. http://dx.doi.org/10.1371/journal.pone.0033495.
35. Kim DY, Kwon E, Hartley PD, Crosby DC, Mann S, Krogan NJ, Gross JD. 2013. CBFβ stabilizes HIV Vif to counteract APOBEC3 at the expense ofRUNX1target gene expression. Mol. Cell 49:632-644. http://dx.doi.org/10.1016/j.molcel.2012.12.012.
36. Hultquist JF, McDougle RM, Anderson BD, Harris RS. 2012. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor beta on genetically distinct surfaces. AIDS Res. Hum. Retroviruses 28:1543-1551. http://dx.doi.org/10.1089/aid.2012.0142.
37. Du J, Zhao K, Rui Y, Li P, Zhou X, Zhang W, Yu XF. 2013. Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta. J. Virol. 87: 1906-1911. http://dx.doi.org/10.1128/JVI.02199-12.
38. Yang HT, Wang JM, Jia XF, McNatt MW, Zang T, Pan BC, Meng WY, Wang HW, Bieniasz PD, Xiong Y. 2010. Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc. Natl. Acad. Sci. U.S.A. 107:18428-18432. http://dx.doi.org/10.1073/pnas.1011485107.
39. Middleton ER, Rhoades E. 2010. Effects of curvature and composition on alpha-synuclein binding to lipid vesicles. Biophys. J. 99:2279-2288. http://dx.doi.org/10.1016/j.bpj.2010.07.056.
40. Simon JH, Sheehy AM, Carpenter EA, Fouchier RA, Malim MH. 1999. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J. Virol. 73:2675-2681.
41. Wolfe LS, Stanley BJ, Liu C, Eliason WK, Xiong Y. 2010. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. J. Virol. 84:7135-7139. http://dx.doi.org/10.1128/JVI.00031-10.